The selectivity of this targeting arises from two factors: overexpressed EGFR on the surface of the tumor cells and greater tumor access due to extensive mucosal barrier disruption at the bladder tumor site compared to normal urothelium. This evidence concerns the gene EGFR and urinary bladder neoplasm.